The ETS Gene ETV4 Is Required for Anchorage-Independent Growth and a Cell Proliferation Gene Expression Program in PC3 Prostate Cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Chromosomal abnormalities that give rise to elevated expression levels of the ETS genes ETV1, ETV4, ETV5, or ERG are prevalent in prostate cancer, but the function of these transcription factors in carcinogenesis is not clear. Previous work in cell lines implicates ERG, ETV1, and ETV5 as regulators of invasive growth but not transformation. Here we show that the PC3 prostate cancer cell line provides a model system to study the over-expression of ETV4. Migration assays, anchorage independent growth assays, and microarray analysis indicate that high ETV4 expression contributes to both transformation and cellular motility in PC3 cells. ETV4 directly bound the 5' and 3' MYC enhancers and modulated expression of both MYC and other cell proliferation genes, demonstrating a potential role in cell growth control. Despite this novel role for ETV4 in anchorage independent growth, ETV4 over-expression in normal prostate-derived RWPE-1 cells showed effects similar to ETV1 over-expression - increased cellular motility, and an up-regulation of genes encoding extracellular proteins as well as ones important for development, inflammation, and wound healing. Because ETV1 and ETV4 have similar roles when introduced to the same cellular background, we suggest that the requirement of high ETV4 expression for maintenance of the anchorage-independent growth in PC3 cells is due to a specific characteristic of this cell line rather than a function of ETV4 that is distinct from the other oncogenic ETS genes. Thus, the function of ETS genes in prostate cancer may differ based on other genetic alterations in a tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 2,156
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
The ETS-domain transcription factor family
Sharrocks, A. D. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099076 · Cited by 1,086 · cited 1×
“The ETS family transcription factors, including the 28 human paralogs, all have a conserved ETS DNA binding domain.(10,11) This results in similar DNA sequence recognition throughout the family and the potential for overlapping transcriptional targets.”
BackgroundAndrogen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902 · cited 1×
“It has been reported recently that the enhancer regions accessible for AR binding differ between androgen-independent and -dependent cells.(27) Interestingly, the types of genes associated with enhancers preferentially targeted in androgenindependent cells are similar to the genes downregulated by ETV4 knockdown in PC…”
BackgroundDistinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844 · cited 5×
“Previous studies indicate that the exogenous expression of ERG, ETV1, and ETV5 in cell lines derived from normal prostate increases growth in invasion assays but does not promote transformation in anchorage-independent growth assays.(6,13,14) Similarly, reduction of ERG or ETV1 expression in V-CAP or LN-CAP prostate c…”
BackgroundMethodResultInfluentialTelomerase maintains telomere structure in normal human cells
Kenichi, M., Yu, E. Y., Shilagardi, K., Ben‐Porath, I., Currier, J. L., Metz, G. B., Brooks, M. W., Kaneko, S., Seishi, M., DeCaprio, J. A., et al. (2006) · Kanazawa University Repository for Academic Resources (DSpace) (Kanazawa University) · Cited by 738
Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer
Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., Cao, Q., Prensner, J. R., Rubin, M. A., Shah, R. B., et al. (2008) · Neoplasia · doi:10.1593/neo.07822 · Cited by 690
Molecular biology of the Ets family of transcription factors
Oikawa, T., & Yamada, T. (2003) · Gene · doi:10.1016/s0378-1119(02)01156-3 · Cited by 688 · cited 1×
“The ETS family transcription factors, including the 28 human paralogs, all have a conserved ETS DNA binding domain.(10,11) This results in similar DNA sequence recognition throughout the family and the potential for overlapping transcriptional targets.”
BackgroundRecurrent gene fusions in prostate cancer
Kumar-Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2402 · Cited by 664 · cited 2×
“Thus, it has been proposed that these 4 ETS proteins have overlapping or redundant functions that promote prostate carcinogenesis.(8,9) However, the oncogenic mechanism of these ETS proteins is still unclear.”
BackgroundMethod
Cited by
Genomic and biochemical insights into the specificity of ETS transcription factors
Hollenhorst, P. C., McIntosh, L. P., & Graves, B. J. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.79.081507.103945 · Cited by 490
Self-citationETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors
Oh, S., Shin, S., & Janknecht, R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.02.002 · Cited by 249
Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells
Hollenhorst, P. C., Ferris, M. W., Hull, M. A., Chae, H., Kim, S., & Graves, B. J. (2011) · Genes & Development · doi:10.1101/gad.17546311 · Cited by 154
Self-citationmiR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT
Kao, C.-J., Martiniez, A., Shi, X.-B., Yang, J. C., Evans, C. P., Dobi, A., White, R. D., & Kung, H.-J. (2013) · Oncogene · doi:10.1038/onc.2013.200 · Cited by 155
“A similar trend is also observed for PC3 cells expressing ETV4, a close homologue of ERG (50) (data not shown).”
BackgroundAytés, À., Mitrofanova, A., Kinkade, C. W., Lefèbvre, C., Lei, M., Phelan, V., Lekaye, C., Koutcher, J. A., Cardiff, R. D., Califano, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303558110 · Cited by 153
“Notably, these ETS transcription factors have been previously implicated in mediating Ras signaling in prostate (49, 50) and other cancers (51, 52), as well as in regulation of EMT markers, including Snail (53, 54).”
BackgroundETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells
Plotnik, J. P., Budka, J. A., Ferris, M. W., & Hollenhorst, P. C. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku929 · Cited by 127
“Soft agar assays were carried out as described previously (25), with minor modifications.”
BackgroundMethodInfluentialSelf-citationThe hallmarks of castration-resistant prostate cancers
Katsogiannou, M., Ziouziou, H., Karaki, S., Andrieu, C., de Villeneuve, M. H., & Rocchi, P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.003 · Cited by 123
“One of the earliest genetic alterations described to occur in 50% of PC but have also been observed in CR and metastatic PC [144,146], is the overexpression of the ERG oncogene, a member of the large family of ETS transcription factors involved in various biological processes such as cell proliferation, differentiatio…”
BackgroundPellecchia, A., Pescucci, C., Lorenzo, E. D., Luceri, C., Passaro, N., Sica, M., Notaro, R., & Angioletti, M. D. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.20 · Cited by 85
Function and regulation of the PEA3 subfamily of ETS transcription factors in cancer.
Qi, T., Qu, Q., Li, G., Wang, J., Zhu, H., Yang, Z., Sun, Y.-S., Lu, Q., & Qu, J. (2020) · PubMed · Cited by 66
Breast cancer invasion and progression by MMP-9 through Ets-1 transcription factor
Nazir, S. U., Kumar, R., Singh, A., Khan, A., Tanwar, P., Tripathi, R., Mehrotra, R., & Hussain, S. (2019) · Gene · doi:10.1016/j.gene.2019.143952 · Cited by 63
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance
Zarif, J. C., & Miranti, C. K. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.01.013 · Cited by 62
Liu, C., Yu, T., Huang, Y., Cui, L., & Hong, W. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.783787 · Cited by 55
“No effect of ERG knockdown on the TAZ level was observed, which may be because of low basal expression level of ERG and high expression level of ETV1, ETV4, and ETV5 in the PC3 cells (25).”
BackgroundTyagi, N., Deshmukh, S. K., Srivastava, S. K., Azim, S., Ahmad, A., AL-Ghadhban, A., Singh, A. P., Carter, J. E., Wang, B., & Singh, S. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0219 · Cited by 55
“Moreover, a role of ETV4 has also been established in anchorage-independent growth (13), enhanced motility and invasiveness (14), epithelial to mesenchymal transition (10), and tumorigenesis (10, 15).”
BackgroundDisruption of Prostate Epithelial Differentiation Pathways and Prostate Cancer Development
Frank, S. B., & Miranti, C. K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00273 · Cited by 67
“TMPRSS2-Erg upregulates Myc in VCaP cells (77) and Etv4 binds Myc enhancers in PC3 cells (313).”
BackgroundETS transcription factors and prostate cancer: The role of the family prototype ETS-1 (Review)
Wernert, N. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1380 · Cited by 49
Kedage, V., Selvaraj, N., Nicholas, T. R., Budka, J. A., Plotnik, J. P., Jerde, T. J., & Hollenhorst, P. C. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.001 · Cited by 56
“ChIP, ChIP-Seq, and RNA Seq ChIP of indicated proteins was performed from VCaP and RWPE1 cells as described previously (Hollenhorst et al., 2011a) using the same antibodies described for immunoblotting, with slight modifications.”
BackgroundMethodResultInfluentialSelf-citationNikolai, B. C., Lanz, R. B., York, B., Dasgupta, S., Mitsiades, N., Creighton, C. J., Tsimelzon, A. I., Hilsenbeck, S. G., Lonard, D. M., Smith, C. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2383 · Cited by 49
“These results suggest that depletion of HER2 or SRC-3 reduces the expression of multiple transcription factors, including E2F1, which are known to regulate the transcription of genes involved in mitotic progression and proliferation(29-31).”
Puli, O. R., Danysh, B. P., McBeath, E., Sinha, D. K., Hoang, N. M., Powell, R. T., Danysh, H. E., Cabanillas, M. E., Cote, G. J., & Hofmann, M.-C. C. (2018) · Neoplasia · doi:10.1016/j.neo.2018.09.003 · Cited by 46
“[50] Hollenhorst PC, Paul L, Ferris MW, and Graves BJ (2011).”
BackgroundOncogenic ETS Factors in Prostate Cancer
Nicholas, T. R., Strittmatter, B. G., & Hollenhorst, P. C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_18 · Cited by 58
Self-citationRAS/ERK pathway transcriptional regulation through ETS/AP-1 binding sites
Hollenhorst, P. C. (2012) · Small GTPases · doi:10.4161/sgtp.19630 · Cited by 52
Self-citationSelvaraj, N., Budka, J. A., Ferris, M. W., Jerde, T. J., & Hollenhorst, P. C. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-61 · Cited by 46
“These included ERG in VCaP, consistent with a TMRPSS2/ERG rearrangement [11], ETV1 in MDA-PCa-2B, consistent with an ETV1 gene re-arrangement [14], and ETV4 in PC3, consistent with high ETV4 mRNA [25].”
InfluentialSelf-citationCurrie, S. L., Doane, J. J., Evans, K. S., Bhachech, N., Madison, B. J., Lau, D., McIntosh, L. P., Skalicky, J. J., Clark, K. A., & Graves, B. J. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.06.024 · Cited by 48
Self-citationQi, M., Liu, Z., Shen, C., Wang, L., Zeng, J., Wang, C., Li, C., Fu, W., Sun, Y., & Han, B. (2014) · Tumor Biology · doi:10.1007/s13277-014-2993-7 · Cited by 42
“Previous studies suggested two possible mechanisms underlying the role of ETV4 on PCa metastasis in vitro and in vivo: (1) activation of signaling pathways, such as aberrant ERK-MAP kinase pathway [4], enhanced Rho/Rho-associated kinase pathway [12] and active PI3-kinase and Ras signaling [13]; (2) a direct regulation…”
BackgroundSelvaraj, N., Budka, J. A., Ferris, M. W., Plotnik, J. P., & Hollenhorst, P. C. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00982-14 · Cited by 34
“We have previously reported that PC3 cells overexpress the oncogenic ETS protein ETV4 and that ETV4 binds ETS/AP-1 sequences (17, 35).”
BackgroundSelf-citationMesquita, D., Barros-Silva, J. D., Santos, J., Skotheim, R. I., Lothe, R. A., Paulo, P., & Teixeira, M. R. (2015) · Oncotarget · doi:10.18632/oncotarget.2847 · Cited by 38
“for PC3 cells [27], but ETV1 was not considered as overexpressed and the MDA-PCa-2b cell line was not evaluated.”
InfluentialZeng, S., Seifert, A. M., Zhang, J. Q., Kim, T. S., Bowler, T. G., Cavnar, M. J., Medina, B. D., Vitiello, G. A., Rossi, F., Loo, J. K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23173 · Cited by 32
“For example, ETV4 directly regulates MYC and other proliferation genes in prostate cancer cell lines [35].”
BackgroundCosi, I., Pellecchia, A., Lorenzo, E. D., Torre, E., Sica, M., Nesi, G., Notaro, R., & Angioletti, M. D. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00943-w · Cited by 35
Sinkovics, J. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1248 · Cited by 28
“ETS1, ETS4 gene expressions are responsible for anchorageindependent high proliferative tumor cell growth (318).”
BackgroundMus, L. M., Lambertz, I., Claeys, S., Kumps, C., Loocke, W. V., Neste, C. V., Umapathy, G., Vaapil, M., Bartenhagen, C., Laureys, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-57076-5 · Cited by 26
Kherrouche, Z., Monté, D., Werkmeister, E., Stoven, L., de Launoit, Y., Cortot, A. B., Tulasne, D., & Chotteau‐Lelièvre, A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.07.001 · Cited by 28
Sornapudi, T. R., Nayak, R., Guthikonda, P. K., Pasupulati, A. K., Kethavath, S., Uppada, V., Mondal, S., Yellaboina, S., & Kurukuti, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-30122-4 · Cited by 27
Jiang, W., Xu, Y., Chen, X., Pan, S., & Zhu, X. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.07.012 · Cited by 32
“Furthermore, ETV4 is observed to regulate the level of MYC and other cell proliferation genes by targeting the 50 and 30 MYC enhancers.(10) Of note, ETV4 is also necessary for PDZ-binding motif (TAZ) gene transcription in prostate cancer, which has the ability of promoting prostate cancer cell invasion and migration.”
BackgroundAdler, D., Braun, M., Nikolov, P., Boehm, D., Scheble, V. J., Menon, R., Fend, F., Kristiansen, G., Perner, S., & Wernert, N. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.01.018 · Cited by 21
“Finally, ETV-4 has been shown to be required for anchorage-independent growth and cell proliferation gene expression program in prostate cancer cell lines [17], and overexpression of ETV-5 has been reported to result in an increase in cell invasion but not proliferation [18].”
BackgroundSingsuksawat, E., Thuwajit, C., Charngkaew, K., & Thuwajit, P. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0525-z · Cited by 21
“The overexpression of ETV4 impacts on many aspects of tumorigenesis including cell proliferation, invasion and metastasis [23, 25, 26].”
Klein, R. H., Tung, P., Somanath, P., Fehling, H. J., & Knoepfler, P. S. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.07.009 · Cited by 19
The ERG-Regulated LINC00920 Promotes Prostate Cancer Cell Survival via the 14-3-3ϵ–FOXO Pathway
Angeles, A. K., Heckmann, D., Flosdorf, N., Duensing, S. M., & Sültmann, H. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0021 · Cited by 16
“ETV4 has previously been described to be highly expressed in PC-3 when compared with other prostate cell lines (37).”
ResultNanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes
Omabe, K. N., Paris, C., Lannes, F., Taïeb, D., & Rocchi, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050591 · Cited by 17
“Others include Tumor microenvironment, Microtubules, angiogenesis, intracellular signal transductions, DNA damage response, antiapoptotic proteins bcl-2 [13], gene fusion [14], deregulation of tumor suppressor genes [15], alternative splicing phenomenon [16], miRNA-dependent post-transcriptional modification and epige…”
BackgroundETS Fusion Genes in Prostate Cancer
Brenner, J. C., Chinnaiyan, A. M., & Tomlins, S. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6828-8_5 · Cited by 19
Baker, S. J., & Reddy, E. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313997110 · Cited by 10
Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
Li, C., Zhang, J., Wu, Q., Kumar, A., Pan, G., & Kelvin, D. J. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0159 · Cited by 13
“At the same time, PC3 is a cell line with overexpression of ETV4 (a member of the ETS family), which is required for anchorage-independent growth and proliferation in PC3 prostate cells (49).”
BackgroundPark, S., Do, H., Ha, W. T., Han, M., Song, H., Uhm, S. J., Chung, H., & Kim, J.-H. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00985 · Cited by 11
Chen, X., Xin, L. I., & Wu, D. (2019) · Europe PMC (PubMed Central) · doi:10.12122/j.issn.1673-4254.2019.08.01 · Cited by 10
“Keywords: hepatocellular carcinoma; E26 transformation-specific variant 4; drug resistance; apoptosis; proliferation as a co-transcription factor and forms a transcription complex[14]; it also directly binds to the promoter regions to promote the transcription of the downstream target genes such as MYC[15], cyclin D1…”
BackgroundNicholas, T. R., Metcalf, S. A., Greulich, B. M., & Hollenhorst, P. C. (2021) · NAR Cancer · doi:10.1093/narcan/zcab033 · Cited by 12
Self-citationZhang, Y., & Shi, W. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2018-0114 · Cited by 7
Raspin, K., O'Malley, D. E., Marthick, J. R., Donovan, S., Malley, R. C., Banks, A., Redwig, F., Skala, M., Dickinson, J. L., & FitzGerald, L. M. (2022) · The Prostate · doi:10.1002/pros.24300 · Cited by 7
“In PC3 cells, ETV4 overexpression was shown to promote transformation and cellular motility, in addition to directly binding MYC enhancers, suggesting a potential role in tumour growth.(40) The same study demonstrated that ETV4 overexpression also promoted cellular motility but not transformation in normal prostate‐de…”
BackgroundIdentification and characterization of novel ETV4 splice variants in prostate cancer
Cosi, I., Moccia, A., Pescucci, C., Munagala, U., Giorgio, S. D., Sineo, I., Conticello, S. G., Notaro, R., & Angioletti, M. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-29484-1 · Cited by 7
ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer
Shaikhibrahim, Z., OCHSENFAHRT, J., Fuchs, K., Kristiansen, G., Perner, S., & Wernert, N. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1097 · Cited by 5
“Furthermore, ETV-4 has been shown to be required for anchorage-independent growth and cell proliferation gene expression program in PCa cell lines (40).”
Role of tumor necrosis factor alpha-induced protein 6 (TNFAIP6) in tumors: a pan-cancer analysis
Yang, Y., Liu, Z.-G., Yang, Y., Zhang, Z., Wang, X., Li, Y.-L., & Sun, R. (2023) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000017 · Cited by 4
Cai, S., Liu, X., Gao, W., Ye, L., Zhong, Q., & Zhang, X. (2023) · Disease Markers · doi:10.1155/2023/8143581 · Cited by 4
Ambily Nath, I. V., & Nair, A. S. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13981 · Cited by 4
“, 2013), and mimicry of actuated Ras/MAPK cascades (Hollenhorst et al., 2011) in prostate cancers are Received: 14 September 2021 | Revised: 29 October 2021 | Accepted: 6 November 2021 DOI: 10.”
BackgroundXu, L., & Zheng, Q. (2021) · Journal of Oncology · doi:10.1155/2021/5033416 · Cited by 3
Nicholas, T. R., Meng, J., Greulich, B. M., Morris, T. S., & Hollenhorst, P. C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238999 · Cited by 2
“RNA was measured using standard curves as previously described [12] using the 3’ reverse transcription primers and the following 5’ primers: 5’-ACCATCTCCTTCCACAGTGC-3’ for ERG, 5’-CCAACACAGTTTTTGATGCC-3’ for HSPA8, and 5’-GGTGAAATTCTTGGACC GGC-3’ for 18S.”
MethodSelf-citationCosi, I., Moccia, A., Nannelli, C., Rosini, D., Iozzo, M., Sica, M., Luceri, C., Notaro, R., & Angioletti, M. D. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167975 · Cited by 1
Gene Fusions in Prostate Cancer
McDaniel, A. S., & Tomlins, S. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-19983-2_17 · Cited by 1
TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implicationsPreprint
Sekar, A., Chatterjee, R., Selvadurai, B. R., Pal, L. R., Verma, A., Nataraj, N. B., Garcia, D. D., Giri, S., Genna, A., Karatekin, F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.17.633582 · Cited by 1
Phenotypic Impact of ETV4 overxpression in prostate carcinogenesis
Mesquita, D. S. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/1hfs-sz79
Higgins, J. E. (2015) · Deep Blue (University of Michigan)
Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with ETV4 Fusion
Shin, Y. J., Yun, J. W., & Kim, H. S. (2022) · Biomedicines · doi:10.3390/biomedicines10102650 · Cited by 1
“Cellular signaling pathways altered in ETV4-fusion-positive cancer were validated by analyzing microarray data from a previous study [18].”
MethodInfluentialNguetcheu, S. T. (2012) · theses.fr (ABES) · doi:10.70675/8db2191ez021fz475czb1cdzb4e82980b445
Characterization of Pten and Trp53 deficient prostatic tumors in mice
Bizri, R. E. (2018) · theses.fr (ABES) · doi:10.70675/887a45dbz93f0z4790z9840z71a317de4d2f
TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens
Sekar, A., Selvadurai, B. R., Chatterjee, R., Pal, L., Verma, A., Nataraj, N. B., Garcia, D. D., Giri, S., Genna, A., Karatekin, F., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00423-7 · Cited by 2
“Although TMPRSS2 - ETV4 fusions are less frequently overexpressed than TMPRSS2-ERG among human patients, increased abundance of ETV4 promotes tumor growth in xenograft models (Hollenhorst et al, 2011b; Pellecchia et al, 2012).”
Metadata
- Authors
- Hollenhorst, P. C., Paul, L., Ferris, M. W., & Graves, B. J.
- Affiliations
- Indiana University Bloomington (US)
- University of Utah (US)
- Indiana University School of Medicine (US)
- Corresponding author
- Hollenhorst, P. C.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2010-10-01
- Volume
- 1
- Issue
- 10
- Pages
- 1044-1052
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- PMC
- PMC3046414
- OpenAlex
- W2007760033
- Cited by
- 62
- References
- 37
- Citations by year
- 2026: 2 · 2025: 2 · 2023: 4 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 5 · 2013: 5 · 2012: 8
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Utah
- National Cancer Institute (P30CA042014)
- National Institute of General Medical Sciences (R01GM038663)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- ETV4, ETS transcription factors, prostate cancer, anchorage-independent growth, cell proliferation, cell motility, cell transformation, ETV1, ERG, ETV5, PC-3 cells, RWPE-1 cells, extracellular matrix genes, wound healing genes, chromosomal abnormalities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.